RxSight (RXST) to Release Earnings on Thursday

RxSight (NASDAQ:RXST) is expected to release its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect RxSight to post earnings of ($0.19) per share and revenue of $25.63 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 4:30 PM ET.

RxSight (NASDAQ:RXST) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.04). The company had revenue of $33.64 million during the quarter, compared to analysts’ expectations of $39.78 million. RxSight had a negative return on equity of 11.56% and a negative net margin of 21.93%.The company’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.16) EPS. On average, analysts expect RxSight to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

RxSight Trading Down 1.3%

Shares of RXST opened at $8.68 on Tuesday. The business’s 50-day moving average price is $8.78 and its 200 day moving average price is $10.88. The stock has a market capitalization of $355.19 million, a P/E ratio of -10.85 and a beta of 1.16. RxSight has a 1-year low of $6.32 and a 1-year high of $55.57.

Wall Street Analysts Forecast Growth

RXST has been the topic of a number of analyst reports. Needham & Company LLC dropped their price target on RxSight from $22.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Jefferies Financial Group reissued a “hold” rating and issued a $9.00 price target (down previously from $24.00) on shares of RxSight in a research note on Thursday, July 10th. Morgan Stanley cut RxSight from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $20.00 to $9.00 in a research note on Tuesday, July 15th. Wall Street Zen cut RxSight from a “hold” rating to a “sell” rating in a research note on Saturday, July 12th. Finally, Piper Sandler dropped their price target on RxSight from $18.00 to $10.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 9th. One analyst has rated the stock with a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, RxSight currently has an average rating of “Reduce” and an average price target of $10.00.

Institutional Investors Weigh In On RxSight

Institutional investors have recently bought and sold shares of the business. Voleon Capital Management LP acquired a new stake in RxSight during the 2nd quarter worth about $465,000. IHT Wealth Management LLC boosted its position in RxSight by 99.6% during the 2nd quarter. IHT Wealth Management LLC now owns 28,610 shares of the company’s stock worth $372,000 after acquiring an additional 14,275 shares during the period. Brevan Howard Capital Management LP acquired a new stake in shares of RxSight during the 2nd quarter valued at about $171,000. Sei Investments Co. lifted its holdings in shares of RxSight by 70.7% during the 2nd quarter. Sei Investments Co. now owns 43,998 shares of the company’s stock valued at $572,000 after buying an additional 18,220 shares during the last quarter. Finally, Legal & General Group Plc lifted its holdings in shares of RxSight by 5.0% during the 2nd quarter. Legal & General Group Plc now owns 44,574 shares of the company’s stock valued at $579,000 after buying an additional 2,121 shares during the last quarter. 78.78% of the stock is currently owned by institutional investors and hedge funds.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.